REPORT FROM EAN 2024 – WEDNESDAY, JULY 3, 2024
July 3, 2024…D20 therapy. At one year, 5 of 8 had no new T2 lesions, 7 of 8 were relapse-free and none experienced disability progression. Five patients achieved no evidence of disease activity (NEDA). Status epilepticus worsens brain tumour outcomes A German study examined the impact of status epilepticus (SE) on function and mortality in 208 patients with brain tumours (Strzelczyk et al. EAN 2024). Mean age was 61.5 years; the most frequent tumour type was a…